The 2nd Annual Biomarkers for Alzheimer’s Disease Summit is the industry’s only digital forum dedicated to sharing innovations in identifying new novel biomarkers and solving the challenges of developing clinically validated […]

With 5 currently approved PI3K inhibitors in the market, and countless investments, M&As and candidates entering the clinical stages, the PI3K pathways space has experienced significant growth in recent years. […]

Overcome Translational & Clinical Challenges to Develop Disease-Modifying Drugs for IPF, the Archetypal Fibrotic Disease. From Dissecting Mechanisms of Epithelial Dysfunction to Discovering Patient Reported Outcomes for More Meaningful Clinical Trials, […]